GlassScriptPhysician profile
Miriam Keena
NPI 1417502758
$3,426.09
in general payments reported to CMS, 2019-2025
21 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what 87% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $456 · 2022: $1,129 · 2023: $531 · 2024: $176 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,681 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,681.30 |
| Education | $159.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,187.57 | 2021-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $296.77 | 2022-2025 | Keytruda |
| Janssen Pharmaceuticals, INC | $248.72 | 2021-2024 | Xarelto |
| Janssen Biotech, INC. | $150.00 | 2025 | Rybrevant, Carvykti |
| Pfizer INC. | $145.80 | 2025 | |
| Genentech USA, INC. | $144.47 | 2022 | |
| Genzyme Corporation | $125.00 | 2022 | |
| Idorsia Pharmaceuticals US INC | $124.47 | 2022 | |
| Springworks Therapeutics, INC. | $122.19 | 2025 | Ogsiveo |
| E.R. Squibb & Sons, L.L.C. | $112.81 | 2025 | Opdivo |
| Shield Therapeutics INC | $107.76 | 2024 | |
| Stemline Therapeutics INC. | $105.47 | 2023 | Orserdu |
| Incyte Corporation | $105.18 | 2025 | Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $96.66 | 2023 | |
| Gilead Sciences, INC. | $90.70 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $87.37 | 2023 | Trudhesa |
| Astellas Pharma US INC | $80.00 | 2025 | |
| Glaxosmithkline, LLC. | $27.44 | 2025 | Zejula, Jemperli |
| Tactile Systems Technology INC | $27.39 | 2025 | Nimbl, Flexitouch Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.00 | 2023 | Jardiance |
| Myriad Genetic Laboratories, INC. | $16.32 | 2024 | Prolaris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miriam Keena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.